Dimensional Fund Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Dimensional Fund Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$247K	Hold	21,128	–	–	﹤0.01%	3036
2026 Q2	$411K	Sell	21,128 -5,179	-20%	-$93.9K	﹤0.01%	2987
2026 Q1	$490K	Sell	26,307 -157,245	-86%	-$2.6M	﹤0.01%	2945
2025 Q4	$2.42M	Buy	183,552 +172,550	+1,568%	+$2.04M	﹤0.01%	2698
2025 Q3	$78.9K	Sell	11,002 -41,717	-79%	-$2.17M	﹤0.01%	3213
2025 Q2	$2.49M	Sell	52,719 -775	-1%	-$31.6K	﹤0.01%	2708
2025 Q1	$2.09M	Sell	53,494 -10,890	-17%	-$469K	﹤0.01%	2715
2024 Q4	$3.49M	Buy	+64,384	New	+$3.29M	﹤0.01%	2640

Other funds holding MLTX

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Achmea Investment Management Zeist, Netherlands $12.6B AUM 25.68% 1-Year Est. Return

BankPlus Wealth Management Jackson, Mississippi $229M AUM 13.58% 1-Year Est. Return

Bayforest Capital London, United Kingdom $67.6M AUM 26.56% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Arizona State Retirement System Phoenix, Arizona $20.3B AUM 36.55% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Dimensional Fund Advisors's MLTX Position: Q3 2026 in Review

Dimensional Fund Advisors held its MoonLake Immunotherapeutics (MLTX) position steady in Q3 2026 at 21,128 shares worth $247K. The position accounts for ﹤0.01% of the portfolio, ranked #3036.

Dimensional Fund Advisors first reported a position in MLTX in Q4 2024 and has held it in 8 quarters since. The position peaked at $3.49M in Q4 2024. 28 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.

Dimensional Fund Advisors held 21,128 shares of MoonLake Immunotherapeutics worth $247K as of Q3 2026.
Dimensional Fund Advisors left its MoonLake Immunotherapeutics share count unchanged in Q3 2026.
MoonLake Immunotherapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #3036 holding.
Dimensional Fund Advisors first reported a position in MoonLake Immunotherapeutics in Q4 2024 and has held it in 8 quarters since.
Dimensional Fund Advisors's MoonLake Immunotherapeutics position peaked at $3.49M in Q4 2024.
28 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.